Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients
Ist Teil von
Cancer gene therapy, 2010-11, Vol.17 (11), p.814-825
Ort / Verlag
New York: Nature Publishing Group US
Erscheinungsjahr
2010
Quelle
MEDLINE
Beschreibungen/Notizen
Multiple endocrine neoplasia type 1 (MEN1) syndrome is characterized by the occurrence of tumors of parathyroids, neuroendocrine cells of the gastro-enteropancreatic tract and anterior pituitary.
MEN1
gene encodes menin-oncosuppressor protein. Loss of heterozygosity at 11q13 is typical of MEN1 tumors. We have analyzed the
MEN1
mRNA and menin expression in fibroblasts from normal skin biopsies and from MEN1 patients (two with a frameshift
738del4
(exon 3) mutation, introducing a premature stop codon, and an individual with an
R460X
(exon 10) nonsense mutation). The expression of full-length menin protein did not differ between MEN1 and normal fibroblasts. Wild-type alleles mRNAs were expressed in MEN1 patients, whereas mutant alleles were partially degraded by nonsense-mediated mRNA decay pathway, suggesting a mechanism of compensation for allelic loss by the up-regulation of wild-type menin expression at a post-transcriptional level. Small-interfering RNA silencing of the wild-type mRNA allele abolished menin compensation, whereas the ribozyme silencing of the
MEN1-
mutated mRNA allele resulted in strongly enhanced wild-type menin expression. Gel-retardation analysis showed that
in vitro-
specific RNA–protein complexes bound to
MEN1
mRNA. These findings contribute to the understanding of tumorigenesis in MEN1, offering the basis for the development of RNA-based therapies in
MEN1
gene mutation carriers.